RxDoctor Payments Data

Salam Zakko, MD

Gastroenterology · Bristol, CTNPI 1801852934

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Salix Pharmaceuticals, A Division Of Bausch Health US, LLC accounts for 82.4% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2019 at $22,540 and has fallen 93.6% since, to $1,444 in 2025.

$28,172in general payments, 2019–2025

Across 325 payments — averaging $86.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$23K
  • AbbVie$767
  • Takeda Pharmaceuticals U.S.A., Inc.$612
  • Echosens North America, Inc.$570
  • Bristol Myers Squibb$323
  • Madrigal Pharmaceuticals$275
  • plus $2K from 27 others
$2,711,837in research payments, 2019–2025

Across 361 payments — averaging $7512.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bristol Myers Squibb$1.1M
  • Pfizer$602K
  • Takeda Pharmaceuticals U.S.A., Inc.$249K
  • Bausch Health US, LLC$214K
  • Braintree Laboratories, Inc.$212K
  • Ironwood Pharmaceuticals, Inc$155K
  • plus $228K from 7 others

What the payments were for

  • Consulting fees$2,0137%
  • Speaking & faculty fees$15,60055%
  • Travel & lodging$2,87610%
  • Food & beverage$7,68327%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,172 in reported general payments places this provider in the 85th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$66,258
Medicare patients
267
Services billed
1,436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dexlansoprazole DrDexlansoprazole28$12,845
Ursodiol12$1,899
Lansoprazole21$1,184
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates17$977
Omeprazole45$882
Pantoprazole Sodium70$872
Esomeprazole Magnesium25$733
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl35$646
Rabeprazole Sodium16$376

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Bristol

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →